The results showed that YAP1, the oncogenic effector of the Hippo pathway, was frequently (11%) amplified, while LATS1/2, MST1, and FATs, which are upstream tumor suppressors of the Hippo pathway, were frequently deleted or mutated in cervical cancer patients (Figure S1A). Here, C10orf90 is linked to cervical cancer.